CD274 and non-small cell lung carcinoma: We identified 317 NSCLC patients treated at Institut Curie, who met the inclusion criteria: patients with histologically proven advanced NSCLC who received anti-PD-(L)1 immunotherapy, specifically pembrolizumab, as their first-line treatment.